Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
Status:
Completed
Trial end date:
2018-06-12
Target enrollment:
Participant gender:
Summary
Evaluate the effect of regorafenib on the pharmacokinetics of digoxin (P-gp substrate :
P-glycoprotein) and rosuvastatin (BCRP substrate: Breast cancer resistant protein) by
comparing their Area under time curve (AUC(0-24)) and maximum drug concentration (Cmax) on
Day -7 and Cycle 1 or Cycle 2 Day 15 of regorafenib in cancer patients